This study is to preform a comparative pharmacokinetic study of Dronabinol XL AdVersa® versus the listed drug.

Trial Profile

This study is to preform a comparative pharmacokinetic study of Dronabinol XL AdVersa® versus the listed drug.

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Dronabinol (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Pharmacokinetics
  • Most Recent Events

    • 01 Dec 2017 New trial record
    • 28 Nov 2017 According to a Tetra Bio-Pharma media release, company expects to complete the analysis of the trial and announce results in the fourth quarter of 2018. Followed by a NDA submission in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top